Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.

CONCLUSION: The PASCO I study contributes significantly to current knowledge about the frequency of adverse events associated with the use of epoetin-ζ for the treatment of renal anemia and demonstrates a pattern of adverse events comparable with data for other existing epoetin products in Europe. PMID: 26396097 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26396097?dopt=Abstract

Source: Clinical Nephrology - September 23, 2015 Category: Urology & Nephrology Authors: Dellanna F, Fluck RJ, Lonnemann G, Wild CA, Iwanowitsch A, Meissner R, Audhya P Tags: Clin Nephrol Source Type: research